Skip to content

Study · Randomized controlled trial · n = 23 · 2017

5 results

Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.

Scalzo RL, Moreau KL, Ozemek C, Herlache L, McMillin S, Gilligan S, Huebschmann AG, Bauer TA, Dorosz J, Reusch JE, Regensteiner JG

Journal of diabetes and its complications7 Oct 2016Cited by 62 (Europe PMC)

PMID27884660 (opens in a new tab)PMCIDPMC5787373 (opens in a new tab)DOI10.1016/j.jdiacomp.2016.10.003 (opens in a new tab)PepBankPUB-27884660
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, exenatide did not improve peak oxygen uptake versus placebo.

    In plain wordsIn people with type 2 diabetes, exenatide did not improve peak oxygen uptake versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePeak oxygen uptake
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    10μg BIDAs given in this study (human).

    Source sentences

    Summary
    Treatment with exenatide did not improve VO2peak (P=0.1464) or VO2 kinetics (P=0.2775).
    1 context sentence
    Summary · context
    Twenty-three participants (64±4years; mean±SE) with uncomplicated T2DM were randomized in a double-blinded manner to receive either 10μg BID of exenatide or matching placebo after baseline measurements.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, exenatide did not improve oxygen uptake kinetics versus placebo.

    In plain wordsIn people with type 2 diabetes, exenatide did not improve oxygen uptake kinetics versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeOxygen uptake kinetics
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    10μg BIDAs given in this study (human).

    Source sentences

    Summary
    Treatment with exenatide did not improve VO2peak (P=0.1464) or VO2 kinetics (P=0.2775).
    1 context sentence
    Summary · context
    Twenty-three participants (64±4years; mean±SE) with uncomplicated T2DM were randomized in a double-blinded manner to receive either 10μg BID of exenatide or matching placebo after baseline measurements.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, exenatide reduced resting lateral E:E' versus placebo.

    In plain wordsIn people with type 2 diabetes, exenatide improved heart relaxation versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDiastolic function
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10μg BIDAs given in this study (human).

    Measurements

    Resting lateral E:E'
    7.6 E:E' ratio
    placebo, pre-treatment
    Resting lateral E:E'
    8.4 E:E' ratio
    placebo, post-treatment
    Resting lateral E:E'
    8.1 E:E' ratio
    exenatide, pre-treatment
    Resting lateral E:E'
    6.7 E:E' ratio
    exenatide, post-treatment

    Source sentences

    Summary
    Diastolic function, assessed via resting lateral E:E', was improved with administration of exenatide compared with placebo (Placebo Pre: 7.6±1.0 vs. Post: 8.4±1.2 vs. Exenatide Pre: 8.1±0.7 vs. Post: 6.7±0.6; P=0.0127).
    1 context sentence
    Summary · context
    Twenty-three participants (64±4years; mean±SE) with uncomplicated T2DM were randomized in a double-blinded manner to receive either 10μg BID of exenatide or matching placebo after baseline measurements.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, exenatide reduced arterial stiffness measured by pulse wave velocity versus placebo.

    In plain wordsIn people with type 2 diabetes, exenatide reduced artery stiffness versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePulse wave velocity
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10μg BIDAs given in this study (human).

    Measurements

    Pulse wave velocity
    10.5 s
    placebo, pre-treatment
    Pulse wave velocity
    11.5 s
    placebo, post-treatment
    Pulse wave velocity
    11.4 s
    exenatide, pre-treatment
    Pulse wave velocity
    10.2 s
    exenatide, post-treatment

    Source sentences

    Summary
    Additionally, arterial stiffness measured by pulse wave velocity, was reduced with exenatide treatment compared with placebo (Placebo Pre: 10.5±0.8 vs. Post: 11.5±1.1s vs. Exenatide Pre: 11.4±1.8 vs. Post: 10.2±1.4s; P=0.0373).
    1 context sentence
    Summary · context
    Twenty-three participants (64±4years; mean±SE) with uncomplicated T2DM were randomized in a double-blinded manner to receive either 10μg BID of exenatide or matching placebo after baseline measurements.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, exenatide did not improve endothelial function versus placebo.

    In plain wordsIn people with type 2 diabetes, exenatide did not improve blood vessel lining function versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeEndothelial function
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10μg BIDAs given in this study (human).

    Source sentences

    Summary
    Exenatide treatment did not improve endothelial function (P=0.1793).
    1 context sentence
    Summary · context
    Twenty-three participants (64±4years; mean±SE) with uncomplicated T2DM were randomized in a double-blinded manner to receive either 10μg BID of exenatide or matching placebo after baseline measurements.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.